News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Expanding Our Capabilities: Dr. Khurshid Iqbal Joins KBI BioPharma



10/19/2005 5:09:16 PM

DURHAM, N.C., Sept. 12 /PRNewswire/ -- KBI BioPharma, Inc. announces the addition of Khurshid Iqbal, Ph.D., Sr. Vice President, Biopharmaceutical Development, to the KBI BioPharma team to head the scientific and business development groups.

Dr. Iqbal has over 25 years of domestic and international experience in pharmaceutical product development. Prior to joining KBI BioPharma, Dr. Iqbal held key scientific positions in well-known pharmaceutical organizations such as R.W. Johnson Pharmaceutical Research Institute, Hoffman-La Roche, E.R. Squibb & Sons and most recently as Senior Vice President, West Pharmaceuticals, a leading drug delivery and device organization.

Dr. Iqbal earned his Ph.D. in Pharmacokinetics from The University of Sciences, Philadelphia (formerly The Philadelphia College of Pharmacy and Science). He has published consistently in the field of biopharmaceutical formulation development and stabilization of proteins and peptides and drug delivery applications. Dr. Iqbal was elected as the section chair of the Biotech section of The American Association of Pharmaceutical Scientists (AAPS) in 1992 and has remained active with the growth of this section at AAPS. He is a member of the Society of the Sigma Xi, AAPS, PDA and Controlled Release Society.

"Dr. Iqbal brings vast experience in biopharmaceutical dosage form development and will be instrumental in moving KBI BioPharma's biopharmaceutical services to the forefront of the contract research industry, beginning with our pilot scale lyophilization and a variety of formulation development services," says Tony Laughrey, CEO. "Dr. Iqbal provides the leadership, expertise and experience needed to further expand our development services.

For more information, please visit our website at www.kbibiopharma.com.

About KBI BioPharma, Inc.

KBI BioPharma, Inc. is a contract services organization committed to reducing process development time, decreasing production cost and increasing speed of development for biopharmaceuticals. As part of our comprehensive service offering, we provide a full range of preformulation (conformational and chemical stability), formulation development (lyophilization, liquid, gel, suspension, sterile/non sterile), analytical method development and validation, toxicological supplies, ICH stability studies and quality and regulatory support. Our services are carried out in state-of-the-art laboratories housed in our 341,000 sq. ft. campus in Durham, North Carolina. KBI BioPharma's management and staff utilize their expertise in biopharmaceutical services to deliver a high-quality technical package to our customer.

KBI BioPharma, Inc.

CONTACT: Joe McMahon, VP - Operations, ext. 2002, or Timothy Albury,Investor Relations, ext. 2006, both of KBI BioPharma, Inc., +1-919-479-9898


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES